Parkinson's disease is characterized by the sudden degeneration and death of neurons that secrete dopamine in the brain. Accumulation of reactive oxygen species damages the neurons, by contributing to the onset of mitochondrial dysfunction, neuroinflammation, and neuronal death. Researchers at the Center for Nanoparticle Research, within the Institute for Basic Science (IBS, South Korea), have developed a set of nanoparticles for Parkinson’s disease (lat. Parkinson scriptor morbus) treatment. Tested in mice, this study represents the first biomedical application of nanoparticles in the clearance of reactive oxygen by-products in Parkinson’s, and gives new hints of therapeutic targets. In the future, the system is expected to be used in the identification and treatment of other pathologies caused by reactive oxygen species, including cancers, cardiovascular diseases, neurodegenerative diseases, and sepsis.